Price movement over the last 24 hours
ADMA Biologics Inc vs Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 — how do they compare? ADMA Biologics Inc trades at $9.23 (market cap $2.13B), while Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 trades at $45.98. Which is the better fit depends on your goals.
| ADMA | USOI | |
|---|---|---|
Market Cap | $2.13B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $20.38 | $61.17 |
52-Week Low | $7.60 | $42.27 |
Enterprise Value | $2.20B | — |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
USOI trades at $42.51, up 0.45% today, but technical indicators show a bearish trend with moving averages unanimously signaling sell. The exchange-traded note (ETN) yields over 30% by selling covered calls on crude oil futures, benefiting from recent oil market volatility driven by geopolitical tensions. However, key financial ratios are unavailable, limiting fundamental visibility.
Outlook hinges on oil price stability and volatility harvesting, but risks include capped upside from the call strategy and ETN structure complexities. Investors face high yield potential offset by exposure to oil market swings and potential issuer credit risk, requiring careful risk assessment.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →USOI is an Exchange-Traded Note (ETN) issued by UBS that provides exposure to a covered call strategy on the United States Oil Fund (USO). It aims to generate high monthly income by capturing option premiums from the hypothetical sale of out-of-the-money call options on oil shares, offering a way to profit from crude oil's volatility even in a flat or range-bound market.
Read more on USOI →